Novo Nordisk announced price reductions for three of its most popular medications:¹

• Wegovy
• Ozempic
• Rybelsus

According to the company, the decrease is part of a move to expand access to the popular medications. Starting on January 1, 2027, the list price for these medications will drop to $675-per-month for each drug.

Which doses of GLP-1 medications will be impacted by Novo Nordisk’s price reduction?

This price will be in effect for the following dosages:

• 2.4 mg Wegovy injection
• 25 mg Wegovy tablets
• 0.5 mg, 1 mg, and 2 mg Ozempic injections
• 7 to 14 mg Rybelsus tablets

In a press release, Novo Nordisk’s executive vice president of US operations Jamey Millar said, “Lowering the list price of Wegovy® and Ozempic® is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States. Private and public payers, as well as patients, want access and have been calling for lower list prices. Our actions today answer that call and remove cost barriers so the value of Wegovy® and Ozempic® can be realized by more patients. The lower list price is intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or co-insurance benefit designs.”

The announcement notes that the price decrease will only impact the list price. Patients purchasing the drugs through direct-to-consumer portals will not be impacted by these changes.

The announcement comes as competition in the GLP-1 space continues to increase for Novo Nordisk. Earlier this month, Eli Lilly issued a regulatory filing revealing a $1.5 billion pre-launch inventory for its weight-loss drug orforglipron. The company is expecting an announcement from FDA on the drug’s approval, and the size of the stockpile reveals how strong Eli Lilly expects that potential launch to be.

Novo Nordisk also took steps to protect its position in the weight-loss market by going after knock-off versions of its drugs. In February, the company successfully took legal action against Hims & Hers to prevent the company from selling unapproved, compounded versions of Wegovy and Ozempic.²

In a press release, John F. Kuckelman, senior vice president, group general counsel, global legal, IP, and security for Novo Nordisk, said, “Throughout Novo Nordisk’s 103-year-long history, patient safety has always been our top priority. Hims & Hers is mass marketing unapproved knock-off versions of Wegovy® and Ozempic® that evade the FDA’s gold standard review process––that’s dangerous and deceptive to patients and undermines the scientific innovation and regulatory rigor in place to ensure these treatments are safe and effective. We’ve taken legal action to protect the American public and our intellectual property and will continue to work with regulators, law enforcement, and other key stakeholders to ensure patients have access to FDA approved safe and effective medicines.”

Also in February, Novo Nordisk announced approval from the European Commission for a more effective dose of the injectable form of Wegovy.³ The approval allows for a higher dose of 7.2 mg for maintenance in weight loss patients.

Emil Kongshøj Larsen, executive vice president of international operations at Novo Nordisk, said in a press release, “This approval is another important step in helping people living with obesity reach very significant weight loss. The new dose gives healthcare professionals even more flexibility to tailor treatment and help people with obesity achieve their weight loss and health goals.”

Sources

1. Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access. Novo Nordisk. February 24, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916504
2. Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy and Ozempic. Novo Nordisk. February 9, 2026. Accessed February 24, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916493
3. Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy for adults with obesity; clinical study showed people lost about 21% of their body weight on average. Novo Nordisk. February 17, 2026. Accessed February 24, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916499